Search results
Results From The WOW.Com Content Network
AstraZeneca plc (/ ˌæstrəˈzɛnəkə /) (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company [2][3][4] with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. [5] It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection ...
COVID-19 vaccination roll out in AIIMS, New Delhi, India on 16 January 2021. India began its vaccination programme on 16 January 2021, operating 3,006 vaccination centres on the onset. [ 23 ] Each vaccination centre will offer either Covishield or Covaxin, but not both.
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield[31] and Vaxzevria[1][32] among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, [33][34][35] using as a vector the modified chimpanzee adenovirus ChAdOx1. [36] The vaccine is given by ...
The Serum Institute of India (SII), which produced AstraZeneca's COVID-19 vaccine under the brand name Covishield, stopped manufacturing and supply of the doses since December 2021, an SII ...
AstraZeneca’s COVID-19 vaccine provided strong protection against sickness and eliminated hospitalizations and deaths from the disease across all age groups in a late-stage study in the United ...
India has put a temporary hold on all major exports of the AstraZeneca coronavirus shot made by the Serum Institute of India (SII), the world's biggest vaccine-maker, to meet domestic demand as ...
Serum Institute of India partnered with the British-Swedish multinational pharmaceutical company AstraZeneca for developing AZD1222 (Covishield) in partnership with the University of Oxford. [19] It was reported that Serum Institute of India would provide 100 million (10 crore) doses of the vaccine for India and other low and middle-income countries. [20][21][22] This target was later ...
India is expected to start a massive immunisation programme within about a week, and hopes to inoculate 300 million of its 1.35 billion people free of charge in the first six to eight months of ...